244 related articles for article (PubMed ID: 34138742)
1. Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non-small cell lung cancers.
Han J; Yu R; Duan J; Li J; Zhao W; Feng G; Bai H; Wang Y; Zhang X; Wan R; Xu J; Wang X; Guan Y; Xia X; Yao Z; Fei K; Carbone DP; Wang Z; Wang J
Sci Adv; 2021 May; 7(21):. PubMed ID: 34138742
[TBL] [Abstract][Full Text] [Related]
2. Predictive and Prognostic Implications of Circulating CX3CR1
Abdelfatah E; Long MD; Kajihara R; Oba T; Yamauchi T; Chen H; Sarkar J; Attwood K; Matsuzaki J; Segal BH; Dy GK; Ito F
Cancer Res Commun; 2023 Mar; 3(3):510-520. PubMed ID: 37009132
[TBL] [Abstract][Full Text] [Related]
3. TCR Repertoire Diversity of Peripheral PD-1
Han J; Duan J; Bai H; Wang Y; Wan R; Wang X; Chen S; Tian Y; Wang D; Fei K; Yao Z; Wang S; Lu Z; Wang Z; Wang J
Cancer Immunol Res; 2020 Jan; 8(1):146-154. PubMed ID: 31719056
[TBL] [Abstract][Full Text] [Related]
4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
5. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
6. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
[TBL] [Abstract][Full Text] [Related]
7. CD103
Corgnac S; Malenica I; Mezquita L; Auclin E; Voilin E; Kacher J; Halse H; Grynszpan L; Signolle N; Dayris T; Leclerc M; Droin N; de Montpréville V; Mercier O; Validire P; Scoazec JY; Massard C; Chouaib S; Planchard D; Adam J; Besse B; Mami-Chouaib F
Cell Rep Med; 2020 Oct; 1(7):100127. PubMed ID: 33205076
[TBL] [Abstract][Full Text] [Related]
8. Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer.
Zhang J; Ji Z; Caushi JX; El Asmar M; Anagnostou V; Cottrell TR; Chan HY; Suri P; Guo H; Merghoub T; Chaft JE; Reuss JE; Tam AJ; Blosser RL; Abu-Akeel M; Sidhom JW; Zhao N; Ha JS; Jones DR; Marrone KA; Naidoo J; Gabrielson E; Taube JM; Velculescu VE; Brahmer JR; Housseau F; Hellmann MD; Forde PM; Pardoll DM; Ji H; Smith KN
Clin Cancer Res; 2020 Mar; 26(6):1327-1337. PubMed ID: 31754049
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.
Yan L; Wang Z; Cui C; Guan X; Dong B; Zhao M; Wu J; Tian X; Hao C
Cancer Sci; 2019 Oct; 110(10):3038-3048. PubMed ID: 31385405
[TBL] [Abstract][Full Text] [Related]
10. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Casarrubios M; Cruz-Bermúdez A; Nadal E; Insa A; García Campelo MDR; Lázaro M; Dómine M; Majem M; Rodríguez-Abreu D; Martínez-Martí A; de Castro-Carpeño J; Cobo M; López-Vivanco G; Del Barco E; Bernabé Caro R; Viñolas N; Barneto Aranda I; Viteri S; Massuti B; Barquín M; Laza-Briviesca R; Sierra-Rodero B; Parra ER; Sanchez-Espiridion B; Rocha P; Kadara H; Wistuba II; Romero A; Calvo V; Provencio M
Clin Cancer Res; 2021 Nov; 27(21):5878-5890. PubMed ID: 34376534
[TBL] [Abstract][Full Text] [Related]
12. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
[TBL] [Abstract][Full Text] [Related]
14. Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8
Sheng J; Wang H; Liu X; Deng Y; Yu Y; Xu P; Shou J; Pan H; Li H; Zhou X; Han W; Sun T; Pan H; Fang Y
Front Mol Biosci; 2021; 8():679130. PubMed ID: 34307450
[No Abstract] [Full Text] [Related]
15. Peripheral blood T-cell receptor repertoire as a predictor of clinical outcomes in gastrointestinal cancer patients treated with PD-1 inhibitor.
Ji S; Li J; Chang L; Zhao C; Jia R; Tan Z; Liu R; Zhang Y; Li Y; Yin G; Guan Y; Xia X; Yi X; Xu J
Clin Transl Oncol; 2021 Aug; 23(8):1646-1656. PubMed ID: 33583004
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of T cell receptor repertoire in patients with
Wang Y; Peng L; Zhao M; Xiong Y; Xue J; Li B; Huang Z; Liu X; Yang X; Song Y; Bing Z; Guo C; Tian Z; Gao C; Cao L; Cao Z; Li J; Jiang X; Si X; Zhang L; Li X; Zheng Z; Song M; Chen R; Lim WT; Pavan A; Romero A; Liang N; Yang H; Li S
Transl Lung Cancer Res; 2022 Sep; 11(9):1936-1950. PubMed ID: 36248331
[TBL] [Abstract][Full Text] [Related]
17. Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.
Poran A; Scherer J; Bushway ME; Besada R; Balogh KN; Wanamaker A; Williams RG; Prabhakara J; Ott PA; Hu-Lieskovan S; Khondker ZS; Gaynor RB; Rooney MS; Srinivasan L
Cell Rep Med; 2020 Nov; 1(8):100141. PubMed ID: 33294862
[TBL] [Abstract][Full Text] [Related]
18. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
19. Evodiamine suppresses non-small cell lung cancer by elevating CD8
Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL
J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR
You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H
Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
